“Global cannabidiol market accelerates, powered by soaring adoption in health, beauty, and functional wellness sectors, and a global shift toward natural, plant-based solutions.”
Lifescience
“Global Urology Devices expand rapidly with aging populations, increasing chronic urinary conditions, and the shift toward precision and minimally invasive interventions.”
The global urology devices market encompasses a diverse array of medical instruments and technologies designed for the diagnosis, treatment, and management of urological disorders. These devices include diagnostic tools like cystoscopes and urodynamic systems, therapeutic instruments such as catheters, stents, and laser systems, and surgical equipment used in procedures like prostatectomies and kidney stone removals. The lifecycle of these devices varies depending on their type and usage. Regulatory bodies play a crucial role in overseeing the safety and efficacy of urology devices. In the North America, the Food and Drug Administration regulates medical devices through its Center for Devices and Radiological Health (CDRH), ensuring that all devices meet stringent safety standards before reaching the market. Similarly, in the European Union, the Regulation (EU) 2017/745 on medical devices governs the approval and monitoring of medical devices, including those used in urology. These regulations mandate rigorous testing, quality control, and post-market surveillance to safeguard patient health. Government policies also influence the urology devices market by shaping healthcare infrastructure and reimbursement frameworks. Initiatives aimed at improving healthcare access and quality, such as the expansion of specialized urology departments in hospitals and the training of healthcare professionals, contribute to market growth. The global urology devices market is further propelled by technological advancements that enhance the precision, efficiency, and safety of urological procedures. Innovations such as robotic-assisted surgeries, minimally invasive techniques, and smart diagnostic tools are transforming the landscape of urological care.
According to the research report "Global Urology Devices Market Outlook, 2030," published by Bonafide Research, the Global Urology Devices market was valued at more than USD 37.03 Billion in 2024, and expected to reach a market size of more than USD 56.31 Billion by 2030 with the CAGR of 7.39% from 2025-2030.The global urology devices market is experiencing significant growth, driven by several key factors including technological advancements, strategic mergers and collaborations, and evolving global trade dynamics. Technological innovations have revolutionized urology care, introducing devices that enhance precision and patient outcomes. For instance, robotic-assisted surgical systems, such as the Monarch platform by Johnson & Johnson, offer minimally invasive options for procedures like kidney stone removal, improving recovery times and reducing complications. Similarly, advancements in imaging technologies, such as high-definition cystoscopes and 3D ultrasound systems, allow for more accurate diagnostics and targeted treatments. These technological strides are not only improving surgical outcomes but also expanding the range of treatment options available to patients. Strategic mergers and collaborations are further accelerating growth in the urology devices market. Companies are increasingly joining forces to combine expertise, expand product portfolios, and enhance market reach. For example, in November 2023, Telix Pharmaceuticals partnered with Mauna Kea Technologies to integrate augmented reality imaging with radiopharmaceuticals in urologic oncology surgery, aiming to improve surgical precision and outcomes. Such partnerships enable companies to leverage synergies, streamline operations, and accelerate the development and distribution of innovative urology devices. In the case of prostate cancer, surgical removal, brachytherapy, and radiation therapy are the most utilized treatments. Treatment selection is witnessing evolution with the development of innovations in robotic-assisted prostatectomy and proton beam radiation therapy. Manufacturers of medical devices are collaborating with research institutions to develop advanced urology devices due to the rising prevalence of end-stage renal diseases, chronic kidney diseases, and urethral malignancies.
Accessories, including catheters, stents, lubricants, gels, and other consumables, hold the largest and fastest-growing share in the global urology devices market, primarily driven by their critical role in diagnosing, treating, and managing a broad spectrum of urological conditions. Catheters, for instance, are indispensable for patients with urinary retention, incontinence, or post-surgical care, ensuring urine drainage and bladder management. Stents are commonly used to relieve obstructions in the ureters or urethra, particularly in conditions like urolithiasis and benign prostatic hyperplasia. The essential nature of these devices ensures consistent usage across hospitals, clinics, and home care settings, contributing to their dominance in the market. The recurring nature of these products significantly fuels market growth. Unlike high-cost capital equipment, which has a limited lifecycle and replacement cycle, consumables like catheters, stents, and gels are used repeatedly and need regular replenishment. Hospitals, urology clinics, and home care providers maintain a steady inventory of these accessories to cater to daily patient needs, creating a reliable and high-volume consumption pattern. This recurring demand makes the accessory segment resilient to market fluctuations and ensures rapid adoption of newer, advanced versions such as antimicrobial-coated catheters, drug-eluting stents, and biodegradable options, which further accelerates market growth. Manufacturers are continuously developing advanced accessories that improve patient outcomes, reduce infections, and enhance procedural efficiency. For example, antimicrobial catheters help prevent urinary tract infections (UTIs), while bioresorbable stents reduce the need for follow-up removal procedures. Such innovations increase the preference for accessory products over other urology devices, driving both market share and growth rate.
Benign Prostatic Hyperplasia (BPH), a non-cancerous enlargement of the prostate gland, represents the largest application segment in the global urology devices market, primarily driven by its widespread prevalence among aging men worldwide. This demographic trend, fueled by increasing life expectancy and the expanding geriatric population globally, underpins the sustained and growing demand for effective urology interventions. BPH leads to lower urinary tract symptoms such as difficulty urinating, frequent urination, and urinary retention, which significantly impacts quality of life and prompts patients to seek medical treatment. The growth of this segment is further accelerated by the rising adoption of minimally invasive procedures and technologically advanced therapies. Traditional surgical interventions, such as transurethral resection of the prostate (TURP), are being gradually replaced by less invasive techniques, including laser therapies, microwave therapies, and prostatic urethral lift devices. These procedures not only reduce complications and recovery time but also require specialized urology devices, driving demand for innovative equipment. The proliferation of such advanced treatment options has created opportunities for device manufacturers to develop high-precision instruments, including bipolar and laser resection tools, endoscopic devices, and image-guided systems, specifically tailored to BPH management. Another contributing factor is the growing awareness and early diagnosis of BPH, especially in developed regions like North America and Europe, where regular health screenings and accessible urological care encourage timely intervention. In emerging markets such as Asia-Pacific and Latin America, increasing healthcare expenditure, improving access to specialized care, and rising awareness about age-related urological disorders are further fueling the demand for BPH-specific devices.
Hospitals and clinics represent the largest end-use segment in the global urology devices market, primarily because these settings are the primary centers for diagnosis, treatment, and long-term management of urological conditions. Urological disorders, including benign prostatic hyperplasia (BPH), urinary incontinence, urolithiasis (kidney stones), and urinary tract infections, are prevalent worldwide and often require specialized interventions that are mostly performed in hospital or clinic settings. Hospitals, ranging from large tertiary care centers to specialized urology hospitals, handle high patient volumes on a daily basis, necessitating a wide array of urology devices, such as catheters, stents, endoscopic instruments, and minimally invasive surgical tools. Many procedures, such as transurethral resection of the prostate, laser lithotripsy, ureteroscopy, and robotic-assisted surgeries, cannot be conducted effectively outside of hospitals or well-equipped clinics. These procedures require sophisticated devices, including high-resolution endoscopes, laser systems, imaging equipment, and supportive accessories such as catheters and stents, ensuring continuous device demand. Geographically, the dominance of hospitals and clinics is particularly pronounced in regions like North America and Europe, where well-developed healthcare infrastructure, insurance coverage, and high patient awareness drive frequent hospital visits and specialist consultations. In emerging markets such as Asia-Pacific and Latin America, rising healthcare expenditure, increasing access to specialized urology care, and the expansion of private hospital networks are contributing to the accelerated growth of this segment. Furthermore, regulatory frameworks in many countries support hospital-based interventions for urological procedures, as these settings ensure compliance with safety, sterilization, and device maintenance standards.
According to the research report "Global Urology Devices Market Outlook, 2030," published by Bonafide Research, the Global Urology Devices market was valued at more than USD 37.03 Billion in 2024, and expected to reach a market size of more than USD 56.31 Billion by 2030 with the CAGR of 7.39% from 2025-2030.The global urology devices market is experiencing significant growth, driven by several key factors including technological advancements, strategic mergers and collaborations, and evolving global trade dynamics. Technological innovations have revolutionized urology care, introducing devices that enhance precision and patient outcomes. For instance, robotic-assisted surgical systems, such as the Monarch platform by Johnson & Johnson, offer minimally invasive options for procedures like kidney stone removal, improving recovery times and reducing complications. Similarly, advancements in imaging technologies, such as high-definition cystoscopes and 3D ultrasound systems, allow for more accurate diagnostics and targeted treatments. These technological strides are not only improving surgical outcomes but also expanding the range of treatment options available to patients. Strategic mergers and collaborations are further accelerating growth in the urology devices market. Companies are increasingly joining forces to combine expertise, expand product portfolios, and enhance market reach. For example, in November 2023, Telix Pharmaceuticals partnered with Mauna Kea Technologies to integrate augmented reality imaging with radiopharmaceuticals in urologic oncology surgery, aiming to improve surgical precision and outcomes. Such partnerships enable companies to leverage synergies, streamline operations, and accelerate the development and distribution of innovative urology devices. In the case of prostate cancer, surgical removal, brachytherapy, and radiation therapy are the most utilized treatments. Treatment selection is witnessing evolution with the development of innovations in robotic-assisted prostatectomy and proton beam radiation therapy. Manufacturers of medical devices are collaborating with research institutions to develop advanced urology devices due to the rising prevalence of end-stage renal diseases, chronic kidney diseases, and urethral malignancies.
Accessories, including catheters, stents, lubricants, gels, and other consumables, hold the largest and fastest-growing share in the global urology devices market, primarily driven by their critical role in diagnosing, treating, and managing a broad spectrum of urological conditions. Catheters, for instance, are indispensable for patients with urinary retention, incontinence, or post-surgical care, ensuring urine drainage and bladder management. Stents are commonly used to relieve obstructions in the ureters or urethra, particularly in conditions like urolithiasis and benign prostatic hyperplasia. The essential nature of these devices ensures consistent usage across hospitals, clinics, and home care settings, contributing to their dominance in the market. The recurring nature of these products significantly fuels market growth. Unlike high-cost capital equipment, which has a limited lifecycle and replacement cycle, consumables like catheters, stents, and gels are used repeatedly and need regular replenishment. Hospitals, urology clinics, and home care providers maintain a steady inventory of these accessories to cater to daily patient needs, creating a reliable and high-volume consumption pattern. This recurring demand makes the accessory segment resilient to market fluctuations and ensures rapid adoption of newer, advanced versions such as antimicrobial-coated catheters, drug-eluting stents, and biodegradable options, which further accelerates market growth. Manufacturers are continuously developing advanced accessories that improve patient outcomes, reduce infections, and enhance procedural efficiency. For example, antimicrobial catheters help prevent urinary tract infections (UTIs), while bioresorbable stents reduce the need for follow-up removal procedures. Such innovations increase the preference for accessory products over other urology devices, driving both market share and growth rate.
Benign Prostatic Hyperplasia (BPH), a non-cancerous enlargement of the prostate gland, represents the largest application segment in the global urology devices market, primarily driven by its widespread prevalence among aging men worldwide. This demographic trend, fueled by increasing life expectancy and the expanding geriatric population globally, underpins the sustained and growing demand for effective urology interventions. BPH leads to lower urinary tract symptoms such as difficulty urinating, frequent urination, and urinary retention, which significantly impacts quality of life and prompts patients to seek medical treatment. The growth of this segment is further accelerated by the rising adoption of minimally invasive procedures and technologically advanced therapies. Traditional surgical interventions, such as transurethral resection of the prostate (TURP), are being gradually replaced by less invasive techniques, including laser therapies, microwave therapies, and prostatic urethral lift devices. These procedures not only reduce complications and recovery time but also require specialized urology devices, driving demand for innovative equipment. The proliferation of such advanced treatment options has created opportunities for device manufacturers to develop high-precision instruments, including bipolar and laser resection tools, endoscopic devices, and image-guided systems, specifically tailored to BPH management. Another contributing factor is the growing awareness and early diagnosis of BPH, especially in developed regions like North America and Europe, where regular health screenings and accessible urological care encourage timely intervention. In emerging markets such as Asia-Pacific and Latin America, increasing healthcare expenditure, improving access to specialized care, and rising awareness about age-related urological disorders are further fueling the demand for BPH-specific devices.
Hospitals and clinics represent the largest end-use segment in the global urology devices market, primarily because these settings are the primary centers for diagnosis, treatment, and long-term management of urological conditions. Urological disorders, including benign prostatic hyperplasia (BPH), urinary incontinence, urolithiasis (kidney stones), and urinary tract infections, are prevalent worldwide and often require specialized interventions that are mostly performed in hospital or clinic settings. Hospitals, ranging from large tertiary care centers to specialized urology hospitals, handle high patient volumes on a daily basis, necessitating a wide array of urology devices, such as catheters, stents, endoscopic instruments, and minimally invasive surgical tools. Many procedures, such as transurethral resection of the prostate, laser lithotripsy, ureteroscopy, and robotic-assisted surgeries, cannot be conducted effectively outside of hospitals or well-equipped clinics. These procedures require sophisticated devices, including high-resolution endoscopes, laser systems, imaging equipment, and supportive accessories such as catheters and stents, ensuring continuous device demand. Geographically, the dominance of hospitals and clinics is particularly pronounced in regions like North America and Europe, where well-developed healthcare infrastructure, insurance coverage, and high patient awareness drive frequent hospital visits and specialist consultations. In emerging markets such as Asia-Pacific and Latin America, rising healthcare expenditure, increasing access to specialized urology care, and the expansion of private hospital networks are contributing to the accelerated growth of this segment. Furthermore, regulatory frameworks in many countries support hospital-based interventions for urological procedures, as these settings ensure compliance with safety, sterilization, and device maintenance standards.
Related Press Releases
Quick Contacts
Trusted Partners
Latest Press Release
We are friendly and approachable, give us a call.